Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its…
New employee representative on the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board…
Novo Tellus completes its transformative growth partnership with Grand Venture Technology
Grand Venture Technology embarks on the next chapter of global growth as…
Novo Tellus wins Private Equity Deal of the Year Award from SVCA with its investment in TDConnex
SINGAPORE, Sept. 22, 2025 /PRNewswire/ -- Novo Tellus, a leading investment firm…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US…
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
BEIJING, July 21, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
